Table 1.
Clinical trials for LAIR-1, LILRB4 and DDR1 in solid and hematologic cancers.
| Target | Drug | Format | Indication | Study | Identifier | Sponsor | Status |
|---|---|---|---|---|---|---|---|
| LAIR-1 | NC410 | LAIR-2 IgG1 fusion protein | Advanced or Metastatic Solid Tumors | A Phase 1/2, Open-Label, Dose-Escalation, Safety and Tolerability Study of NC410 in Subjects With Advanced or Metastatic Solid Tumors | NCT04408599 | NextCure | Recruiting |
| LAIR-1, PD-1 | NC410, Pembrolizumab | LAIR-2 IgG1 fusion protein | Advanced or Metastatic Solid Tumors | A Safety, Tolerability and Efficacy Study of NC410 Plus Pembrolizumab in Participants With Advanced Unresectable or Metastatic Solid Tumors | NCT05572684 | NextCure | Recruiting |
| LAIR-1 | NGM438, Pembrolizumab | N/A | 16 tumor types | A Phase 1/1b Dose Escalation/Expansion Study of NGM438 as Monotherapy and in Combination With Pembrolizumab in Advanced or Metastatic Solid Tumors | NCT05311618 | NGM Biopharmaceuticals, Inc | Active, not recruiting |
| LAIR-1 | NC525 | IgG1 | Relapsed Refractory (R/R) AML, CMML, MDS | A Phase 1, Multicenter, Open-Label, Dose-Escalation and Expansion, Safety, Pharmacokinetic, Pharmacodynamic, and Clinical Activity Study of Intravenously Administered NC525 | N/A | NextCure | Recruiting |
| LILRB4 | IO-202, Azacitidine, Venetoclax | IgG4 | AML With Monocytic Differentiation CMML | A Phase 1, Multicenter, Open-Label, Dose-Escalation and Expansion, Safety, Pharmacokinetic, Pharmacodynamic, and Clinical Activity Study of Intravenously Administered IO-202 and IO-202 + Azacitidine ± Venetoclax in Acute Myeloid Leukemia (AML) Patients With Monocytic Differentiation and in Chronic Myelomonocytic Leukemia (CMML) Patients | NCT04372433 | Immune-Onc Therapeutics | Recruiting |
| LILRB4 | IO-202, Pembrolizumab | IgG1 | Solid Tumor, Adult | A Phase 1, Multicenter, Open-Label, Dose-Escalation, and Dose-Expansion Study of IO-202 in Combination With Pembrolizumab in Subjects With Advanced, Relapsed, or Refractory Solid Tumors | NCT05309187 | Immune-Onc Therapeutics | Recruiting |
| LILRB4 | LILRB4 STAR-T | chimeric antigen receptors (CAR) targeting cells expressing LILRB4 | Relapsed/Refractory Acute Myeloid Leukemia | An Exploratory (Ph1) Clinical Study on the Safety and Efficacy of LILRB4 STAR-T Cells in the Treatment of Relapsed/Refractory Acute Myeloid Leukemia (R/R AML) | NCT05518357 | Hebei Yanda Ludaopei Hospital | Completed |
| LILRB4 and LILRB1 | NGM707, pembrolizumab | Bispecific mAb | 15 tumor types | A Phase 1/2 Dose Escalation/Expansion Study of NGM707 as Monotherapy and in Combination with Pembrolizumab in Advanced or Metastatic Solid Tumor Malignancies | NCT04913337 | NGM Biopharmaceuticals, Inc | Recruiting |
| DDR1 | PRTH-101, pembrolizumab | N/A | Solid Tumors | A First-in-human Study of PRTH-101 Monotherapy +/- Pembrolizumab in Subjects With Advanced Malignancies | NCT05753722 | Parthenon Therapeutics | Recruiting |
N/A, Not available.